| Exosomes: composition, biogenesis and function C Théry, L Zitvogel, S Amigorena Nature reviews immunology 2 (8), 569-579, 2002 | 5681 | 2002 |
| Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 L Galluzzi, I Vitale, SA Aaronson, JM Abrams, D Adam, P Agostinis, ... Cell Death & Differentiation 25 (3), 486-541, 2018 | 5249 | 2018 |
| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4353 | 2018 |
| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 3808 | 2018 |
| Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ... Nature medicine 13 (9), 1050-1059, 2007 | 3334 | 2007 |
| Calreticulin exposure dictates the immunogenicity of cancer cell death M Obeid, A Tesniere, F Ghiringhelli, GM Fimia, L Apetoh, JL Perfettini, ... Nature medicine 13 (1), 54-61, 2007 | 3214 | 2007 |
| Innate or adaptive immunity? The example of natural killer cells E Vivier, DH Raulet, A Moretta, MA Caligiuri, L Zitvogel, LL Lanier, ... science 331 (6013), 44-49, 2011 | 3108 | 2011 |
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ... Science 350 (6264), 1079-1084, 2015 | 3058 | 2015 |
| Immunogenic cell death in cancer therapy G Kroemer, L Galluzzi, O Kepp, L Zitvogel Annual review of immunology 31, 51-72, 2013 | 2985 | 2013 |
| Antigen presentation and T cell stimulation by dendritic cells P Guermonprez, J Valladeau, L Zitvogel, C Théry, S Amigorena Annual review of immunology 20 (1), 621-667, 2002 | 2678 | 2002 |
| Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes L Zitvogel, A Regnault, A Lozier, J Wolfers, C Flament, D Tenza, ... Nature medicine 4 (5), 594-600, 1998 | 2608 | 1998 |
| Immunogenic cell death in cancer and infectious disease L Galluzzi, A Buqué, O Kepp, L Zitvogel, G Kroemer Nature Reviews Immunology 17 (2), 97-111, 2017 | 2310 | 2017 |
| Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ... Nature medicine 15 (10), 1170-1178, 2009 | 2011 | 2009 |
| The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide S Viaud, F Saccheri, G Mignot, T Yamazaki, R Daillère, D Hannani, ... science 342 (6161), 971-976, 2013 | 1943 | 2013 |
| Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming J Wolfers, A Lozier, G Raposo, A Regnault, C Théry, C Masurier, ... Nature medicine 7 (3), 297-303, 2001 | 1901 | 2001 |
| Immunological aspects of cancer chemotherapy L Zitvogel, L Apetoh, F Ghiringhelli, G Kroemer Nature reviews immunology 8 (1), 59-73, 2008 | 1887 | 2008 |
| The immune contexture in cancer prognosis and treatment WH Fridman, L Zitvogel, C Sautès–Fridman, G Kroemer Nature reviews Clinical oncology 14 (12), 717-734, 2017 | 1769 | 2017 |
| Cancer despite immunosurveillance: immunoselection and immunosubversion L Zitvogel, A Tesniere, G Kroemer Nature reviews immunology 6 (10), 715-727, 2006 | 1756 | 2006 |
| Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death N Casares, MO Pequignot, A Tesniere, F Ghiringhelli, S Roux, N Chaput, ... The Journal of experimental medicine 202 (12), 1691-1701, 2005 | 1565 | 2005 |
| Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients F Ghiringhelli, C Menard, PE Puig, S Ladoire, S Roux, F Martin, E Solary, ... Cancer immunology, immunotherapy 56, 641-648, 2007 | 1462 | 2007 |
